No Data
Huaren Pharmaceutical (300110.SZ): Hongta Innovation completes shareholding of 1.00% stake.
Gelonghui November 8th | huaren pharmaceutical (300110.SZ) announced that the company recently received a notice from Hongta innovation regarding the implementation of the shareholding reduction plan for huaren pharmaceutical. The above-mentioned shareholding reduction plan by Hongta innovation has been completed. Hongta innovation has cumulatively reduced its holding of the company's shares by 11,800,000 shares during this shareholding reduction plan period, with a reduction rate of 1.00%.
Huaren Pharmaceutical (300110.SZ): Sodium phosphinate injection obtained pharmaceutical registration certificate.
On November 5th, Hua Ren Pharmaceutical (300110.SZ) announced that the company has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the "Sodium Phosphonoformate Injection". Sodium Phosphonoformate Injection is used for Cytomegalovirus Retinitis in AIDS patients and Acyclovir-resistant Herpes Simplex Virus cutaneous and mucous membrane infection in patients with immune function damage.
Huaren Pharmaceutical's (SZSE:300110) Conservative Accounting Might Explain Soft Earnings
Huaren Pharmaceutical: Report for the third quarter of 2024
Huaren Pharmaceutical (300110.SZ) released its performance for the first three quarters, with a net income of 95.531 million yuan, a decrease of 30.31%.
huaren pharmaceutical (300110.SZ) released the third quarter report of 2024, the company's revenue for the first three quarters of the year was 1...
There Is A Reason Huaren Pharmaceutical Co., Ltd.'s (SZSE:300110) Price Is Undemanding
Investors Give Huaren Pharmaceutical Co., Ltd. (SZSE:300110) Shares A 30% HidingNo Data
No Data
